ArticleChinese journal of integrative medicine2026
Yinchenhao Decoction Alleviates Liver Injury in CYP2D6-Induced Autoimmune Hepatitis Mice: An Integrated Transcriptomic and Proteomic Analysis.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the therapeutic effects of Yinchenhao Decoction (YCHD) on a mouse model of autoimmune hepatitis (AIH) induced by cytochrome P450 2D6 adenovirus (Ad-CYP2D6), and reveal its potential molecular mechanisms through integrated transcriptomic and proteomic analyses.
methodsAIH model was established via tail vein injection of 100 µL Ad-CYP2D6 (1 × 10
resultsCompared with the normal control group, the model group showed significantly increased liver and spleen indices and markedly elevated serum ALT and AST levels, which were markedly reduced following YCHD treatment (P<0.05 or P<0.01). HE staining revealed prominent inflammatory cell infiltration and hepatocyte nuclear loss in the model group; these pathological alterations were significantly ameliorated in the YCHD treatment group. Serum level of specific autoantibody LKM-1 was increased in the model group and significantly reduced following YCHD treatment (P<0.05). Integrated transcriptomic and proteomic analyses demonstrated signal transducer and activator of transcription 1 (Stat1), guanylate-binding protein 3 (Gbp3), and T-cell-specific guanosine triphosphatase 2 (Tgtp2) were significantly upregulated in the model group and were significantly downregulated after YCHD treatment (P<0.05 or P<0.01).
conclusionsYCHD effectively alleviates liver injury in Ad-CYP2D6-induced AIH mice. Its underlying mechanism may be associated with the suppression of interferon-β cellular response pathway mediated by Stat1, Gbp3, and Tgtp2.
Indexed as
Identifiers
42661116What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.